Premier Path Wealth Partners LLC Purchases 3,797 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Premier Path Wealth Partners LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 89.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,052 shares of the biopharmaceutical company's stock after buying an additional 3,797 shares during the quarter. Premier Path Wealth Partners LLC's holdings in Gilead Sciences were worth $744,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of GILD. Massachusetts Financial Services Co. MA increased its position in shares of Gilead Sciences by 0.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 85,804 shares of the biopharmaceutical company's stock valued at $5,887,000 after acquiring an additional 522 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $525,000. MQS Management LLC raised its stake in shares of Gilead Sciences by 33.9% during the 2nd quarter. MQS Management LLC now owns 4,573 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 1,157 shares in the last quarter. Ieq Capital LLC boosted its holdings in shares of Gilead Sciences by 3.7% in the 2nd quarter. Ieq Capital LLC now owns 69,215 shares of the biopharmaceutical company's stock valued at $4,749,000 after buying an additional 2,453 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of Gilead Sciences by 91.4% in the second quarter. Canada Pension Plan Investment Board now owns 2,699,863 shares of the biopharmaceutical company's stock valued at $185,238,000 after buying an additional 1,289,420 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock worth $42,130,461 in the last ninety days. 0.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GILD. Barclays increased their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research note on Thursday, November 7th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Wolfe Research assumed coverage on Gilead Sciences in a research note on Friday, November 15th. They set an "outperform" rating and a $110.00 target price for the company. Oppenheimer increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, December 10th. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $97.96.

Gilead Sciences Price Performance

GILD traded up $0.19 on Friday, hitting $91.84. 6,852,085 shares of the stock were exchanged, compared to its average volume of 5,370,915. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The firm has a market capitalization of $114.46 billion, a price-to-earnings ratio of 1,020.44, a PEG ratio of 1.27 and a beta of 0.18. The business has a 50-day moving average of $91.75 and a two-hundred day moving average of $84.08.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business posted $2.29 EPS. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.